Definium Therapeutics, Inc.
DFTX
Rangering i aksjer
#3756
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
Aksjekurs
$33.11
Markedsverdi
$4.45B
Endring (1 dag)
3.15%
Endring (1 år)
202.77%
Land
US
Handel Definium Therapeutics, Inc. (DFTX)
Kategori
Healthcare
Markedsverdi av Definium Therapeutics, Inc.(DFTX)
Markedsverdi: $4.45B
Per October 2026 har Definium Therapeutics, Inc. en markedsverdi på $4.45B. Dette gjør Definium Therapeutics, Inc. til det 3756th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Definium Therapeutics, Inc. fra 2020 til 2026
DFTX sammenlignet med topp 5 mest populære stocks
